Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep

British Journal of Pharmacology

Volumn 166, Issue 6, 2012, Pages 1916-1925

  Patel, K ^a   Rademaker, Miriam T ^b   Kirkpatrick, C M J ^a,c   Charles, C J ^b   Fisher, S ^b   Yandle, T G ^b   Richards, A M ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Haemodynamics; Pharmacodynamics; Pharmacokinetics; Urocortin 1; Urocortin 2; Urocortin 3

Indexed keywords

UROCORTIN I; UROCORTIN II; UROCORTIN III;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART LEFT VENTRICLE CONTRACTION; HEART OUTPUT MEASUREMENT; HEART RATE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; VASCULAR RESISTANCE;

ANIMALS; HEMODYNAMICS; MODELS, BIOLOGICAL; SHEEP; UROCORTINS;

EID: 84863228226     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01904.x     Document Type: Article

References (35)

1. Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB (2009). The time course of drug effects. Pharm Stat 8: 176-185.
3. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF et al. (2004). The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Nat Acad Sci U S A 101: 3697-3702. (Pubitemid 38338257)
4. Boeckmann AJ, Sheiner LB, Beal S (1994). NONMEM Users Guide -Part V: Introductory Guide, NONMEM Project Group, University of California at San Franciso: San Francisco.
5. Boonprasert P, Lailerd N, Chattipakorn N (2008). Urocortins in heart failure and ischemic heart disease. Int J Cardiol 127: 307-312.
6. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B et al. (2007). Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46: 221-234. (Pubitemid 46425648)
7. Cepoi D, Sutton S, Arias C, Sawchenko P, Vale WW (1999). Ovine genomic urocortin: cloning, pharmacologic characterization, and distribution of central mRNA. Brain Res 68: 109-118. (Pubitemid 29243999)
8. Chanalaris A, Lawrence KM, Stephanou A, Knight RD, Hsu SY, Hsueh AJ et al. (2003). Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol 35: 1295-1305. (Pubitemid 37163536)
9. Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A et al. (2005). Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 328: 442-448. (Pubitemid 40208330)
10. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG et al. (2004). Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab 89: 402-409.
11. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG et al. (2005). Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci 109: 381-388. (Pubitemid 41445245)
12. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM et al. (2007a). Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol 49: 461-471. (Pubitemid 46135883)
13. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM et al. (2007b). Urocortin 2 infusion in human heart failure. Euro Heart J 28: 2589-2597. (Pubitemid 350071510)
14. Dayneka NL, Garg V, Jusko WJ (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478. (Pubitemid 24025269)
15. Fekete EM, Zorrilla EP (2007). Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28: 1-27. (Pubitemid 46533855)
16. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG (1989). Neurohumoral changes during onset and offset of ovine heart failure: role of ANP. Am J Physiol 256: H1052-H1059.
17. Hansson E (2005). Mechanistic and Empiric PK/PD Modelling of the Cardiac Output Effect of Urocortin. Msc, Uppsala University: Uppsala.
18. Hsu SY, Hsueh AJ (2001). Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7: 605-611.
19. Karlsson MO, Holford NH (2008). A tutorial on Visual Predictive Checks. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Available at: http://www.page-meeting.org/?abstract=1434 Vol. Abstract 1434, p. 17.
20. Krzyzanski W, Jusko WJ (1998). Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. J Pharmacokinet Biopharm 26: 385-408. (Pubitemid 29153519)
21. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C et al. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Nat Acad Sci U S A 98: 7570-7575. (Pubitemid 32567989)
22. McGrath J, Drummond G, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Moral MA, Tomillero A (2008). Gateways to clinical trials. Methods Find Exp Clin Pharmacol 30: 149-171. (Pubitemid 351738275)
24. Parkes DG, Vaughan J, Rivier J, Vale W, May CN (1997). Cardiac inotropic actions of urocortin in conscious sheep. Am J Physiol 272: H2115-H2122.
25. Patel K, Kirkpatrick CM (2011). Pharmacokinetic concepts revisited - basic and applied. Curr Pharm Biotechnol 12: 1983-1990.
26. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM et al. (2002). Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 40: 1495-1505. (Pubitemid 35192877)
27. Rademaker MT, Cameron VA, Charles CJ, Richards AM (2005a). Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112: 3624-3632. (Pubitemid 43739541)
28. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM (2005b). Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J 26: 2046-2054. (Pubitemid 41435717)
29. Rademaker MT, Cameron VA, Charles CJ, Richards AM (2006). Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 27: 2088-2098. (Pubitemid 44412817)
30. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA et al. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Nat Acad Sci U S A 98: 2843-2848. (Pubitemid 32209571)
31. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. (2008). Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-146.
32. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25: 358-371. (Pubitemid 9164953)
33. Takahashi K (2004). Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases. Endocr J 51: 1-17.
34. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378: 287-292.
35. Wiley KE, Davenport AP (2004). CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143: 508-514. (Pubitemid 39452218)